BioSpace News Archive

With the new approval, Rubraca becomes the first PARP inhibitor approved in a prostate cancer setting.

U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.

Moderna released positive interim Phase I data from its clinical trial of mRNA-1273, its mRNA vaccine against SARS-CoV-2.

AstraZeneca reported it plans to manufacture as much as 30 million doses of the vaccine for the U.K. market by September, with expectations of 100 million doses by the end of the year.

The results set up the potential for regulatory approval.

Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.

“We are thrilled to have the support of both our new and long-standing investors who believe in SQZ and our potential to create impactful therapies for patients,” said Teri Loxam, SQZ’s chief financial officer.

LIPAC Oncology LLC today announced the presentation of positive interim data from the TD-001 trial evaluating the safety and efficacy of investigational agent LiPax (paclitaxel) for intravesical instillation in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC)

Enzychem Lifesciences, today announced that Dr. Cameron Robert Wolfe, associate professor of medicine at Duke University School of Medicine, an internationally renowned specialist in infectious diseases, has been appointed to lead the Company’s U.S COVID-19 efforts of the development of EC-18 as a COVID-19 therapeutic drug.